Azacitidine appears promising in certain patients with lower-risk myelodysplastic syndrome (MDS), researchers concluded after conducting an analysis involving 233 individuals. Participants were from 6 clinical studies and 1 registry. Investigators looked at red blood cell (RBC) transfusion independence (TI) and clinical benefit. Among the results:
- 9 in every 10 patients had non-del(5q) LR-MDS.
- RBC-TI occurred in 39% of these individuals, and clinical benefit in 81%.
- In patients with isolated anemia, RBC-TI and clinical benefit occurred in 42% and 83%, respectively.
- Plans to use ≥6 azacitidine treatment cycles significantly predicted response.
The authors noted that their findings show that azacitidine works just as well as lenalidomide does in patients with similar characteristics.
Komrokji R, Swern A, Grinblatt D, et al. Azacitidine in lower-risk myelodysplastic syndromes: A meta-analysis of data from prospective studies. [Published online ahead of print November 8, 2017]. Oncologist. doi:10.1634/theoncologist.2017-0215.
This Week's Must Reads
Must Reads in AML
Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al
Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al
Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; Sébert, Komrokji et al
Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al
Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al